Follicular Lymphoma Clinical Trial
Official title:
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) who have received 2 or more prior lines of therapy.
Status | Recruiting |
Enrollment | 206 |
Est. completion date | January 15, 2027 |
Est. primary completion date | January 15, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Inclusion Criteria: - Biopsy proven B-NHL, including DLBCL, HGBL, or FL. - For Arm B Only: Subject has biopsy proven DLBCL or HGBL - For Arm C only: Subject has biopsy proven FL - Subject has received at least 2 lines of therapy to which the subject has been either refractory or has subsequently relapsed. In order to be eligible for this study subjects must not be candidates for treatment regimens known to provide clinical benefit in B-NHL. - Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2. - Subject must have adequate liver, bone marrow and kidney function (eGFR = 50 mL/min). - Subject must have locally confirmed CD19 positivity (must be documented after time of progression from last CD19-targeted therapy, if received) - Subject must have at least 1 measurable disease site - Subject must have ANC >/= 1000/mm3, platelets >/= 50,000 mm3, hemoglobin >/= 8.0 g/dL. Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening - Subject must have a total bilirubin <1.5x ULN, AST/ALT < 3xULN Exclusion Criteria: - Subject has been diagnosed with or treated for another malignancy whose natural history or treatment may interfere with the safety or efficacy assessment of the investigational regimen. - Subject has a history of central nervous system (CNS) involvement by their B-NHL - Subject has a history of leukemic presentation of their B-NHL. - Subject has history or presence of clinically significant CNS pathology - Subject has CNS involvement from active or history of autoimmune disease. - Subject experienced Grade = 3 cytokine release syndrome (CRS) following prior T-cell engager (TCE) or CAR T-cell therapy. - Subject experienced Grade = 2 neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) following prior TCE or CAR T-cell therapy. - Subject has received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study drug treatment or has received an SCT and requires ongoing immunosuppressive therapy. - Subjects with human immunodeficiency virus (HIV) infection, or subjects with chronic or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Subjects with chronic HBV may be enrolled if the HBV viral load is undetectable on suppressive therapy, or if the subject has a documented cure. Subjects with HCV who have a documented cure may be enrolled. - Subject has a history of major cardiac abnormalities. - If female, subject must not be pregnant or breastfeeding. |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Bedford Park | |
Australia | Research Site | Heidelberg | |
Australia | Research Site | Hobart | |
Australia | Research Site | Melbourne | |
Japan | Research Site | Chuo-ku | |
Japan | Research Site | Koto-ku | |
Japan | Research Site | Nagoya-shi | |
Japan | Research Site | Yamagata-shi | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Seoul | |
Taiwan | Research Site | Kaohsiung City | |
Taiwan | Research Site | Kweishan | |
Taiwan | Research Site | Tainan | |
Taiwan | Research Site | Taipei | |
United States | Research Site | Austin | Texas |
United States | Research Site | Charlotte | North Carolina |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Houston | Texas |
United States | Research Site | Louisville | Kentucky |
United States | Research Site | Milwaukee | Wisconsin |
United States | Research Site | New Brunswick | New Jersey |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Portland | Oregon |
United States | Research Site | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Australia, Japan, Korea, Republic of, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of subjects with Dose-limiting toxicities (DLT) | A DLT is defined as a TEAE that is not unequivocally due to the subject's underlying malignancy or other extraneous cause. DLT evaluable subjects are defined as those subjects who receive either the target dose of AZD0486 or priming dose(s) in any step-up dose schedule and are assessed for toxicities for the 28-day evaluation period.
The NCI-CTCAE version 5.0 will be used (except for CRS and NT). A DLT will be evaluated as Non-hematologic, Hematologic, Cytokine Release Syndrome (CRS), or neurotoxicity. |
28 days | |
Primary | Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs) | The incidence, timing, seriousness, and relationship to study treatment of adverse events will be evaluated. | From screening until 90 Days after end of treatment | |
Primary | Maximum Observed Serum Concentration of AZD0486 (Cmax) | The maximum observed serum concentration on a concentration time curve. | 4 weeks | |
Primary | Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) | Area under the serum concentration-time curve from time zero to time of last measurable concentration. | 4 weeks | |
Primary | Apparent terminal half-life (t1/2) of AZD0486 | Terminal half-life (t1/2,) will be determined after infusion in Cycle 1 using non-compartmental methods. | From screening until 90 Days after end of treatment | |
Secondary | Anti-Lymphoma Activity by Objective Response Rate (ORR) | Objective response rate is defined as the proportion of subjects with a confirmed partial or complete response to treatment | 48 months | |
Secondary | Anti-Lymphoma Activity by Progression-Free Survival (PFS) | Progression-free survival time is defined as the time from the first dose of AZD0486 to progression or death, whichever occurs first | 48 months | |
Secondary | Anti-Lymphoma Activity by Duration of Objective Response (DOR) | The duration of objective response for a subject is defined as the time from the initial objective response to disease progression or death, whichever occurs first | 48 months | |
Secondary | Anti-Lymphoma Activity by Clinical Benefit Rate | Clinical benefit rate is defined as the proportion of subjects with a confirmed complete response, partial response or minor response, or stable disease for at least 24 weeks after responding to treatment | 48 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03245021 -
Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A
|
Phase 1 | |
Active, not recruiting |
NCT03078855 -
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
|
Phase 3 | |
Recruiting |
NCT05365659 -
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082936 -
A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02213263 -
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
|
Phase 3 | |
Completed |
NCT01691898 -
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Terminated |
NCT03585725 -
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
|
Early Phase 1 | |
Terminated |
NCT00772668 -
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
|
N/A | |
Recruiting |
NCT02892695 -
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
Terminated |
NCT02204982 -
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
|
Phase 3 | |
Terminated |
NCT00850499 -
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
|
Phase 2 | |
Completed |
NCT02536664 -
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
|
||
Terminated |
NCT00475332 -
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
|
Phase 2 | |
Terminated |
NCT00136591 -
A Phase 2 Study of Velcadeā¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06068881 -
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
|
Phase 2 | |
Completed |
NCT04034056 -
Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
|